LEXINGTON, Ky.- - (BUSINESS WIRE)- - With the continuation of greatly positive clinical results from its initial wellbeing and achievability concentrate on in Malaysia, Intralink-Spine, Inc. (ILS) trusts the Réjuve System is going to change the scene for the treatment of low back agony.
"The smaller scale intrusive Réjuve treatment gives quick nearby basic support of the circle, versus simply utilizing an ESI to treat the agony."
Tweet this
"At the 3-month point, three of the four (3/4) patients have no (zero) low back torment. What's more, the fourth patient has practically no back agony; truth be told, she climbed the Sydney Harbor Bridge two-weeks after the treatment and just came back from exploring and moving in Europe!" says Lyle Hawkins, CEO of Intralink-Spine, Inc. (Message from CEO)
"We keep on being exceptionally satisfied with the patient results. In spite of the fact that restricted to four patients at this stage, these 3-month information are demonstrative that the Réjuve gadget has an additionally enduring impact on low back torment and incapacity than the exceptionally basic epidural steroid infusion (ESI)," says Hawkins. "On the off chance that our VAS and ODI slant lines proceed not surprisingly, Réjuve will have an exceptionally sensational effect on how patients are presently treated for low back torment. In this way, you can comprehend why we keep on being amped up for Réjuve."
"Inside days after the Réjuve treatment, we're seeing patient torment scores drop from 5-7 to 0 on the VAS torment scale, and inability scores drop from more than half to 0 on the ODI. These underlying clinical results exhibit a critical diminishment or disposal of agony, not only a slight lessening in torment, and these advantages are proceeding past the 3-month point. This is incredible news, particularly as we start our bigger crucial clinical studies in the quick months ahead," says Tom Hedman, Ph.D., who is the Chief Scientific Officer for ILS and Adjunct Associate Professor in the F. Joseph Halcomb III, M.D. Branch of Biomedical Engineering at the University of Kentucky. "The smaller scale intrusive Réjuve treatment gives prompt neighborhood basic support of the plate, versus simply utilizing an ESI to treat the torment."
"The patients got fluoroscopic picture guided infusions of the Réjuve medicinal gadget in the lumbar intervertebral circles, with two posterolateral infusions for each treated level", states orthopedic specialist, Dr. Harwant Singh at the Pantai Medical Center, Kuala Lumpur, Malaysia. "The patient ODI and VAS scores at the 3-month interim are great and empowering for the Réjuve treatment."
Contacts
Intralink-Spine Inc.
Lyle Hawkins, 502-419-8099
LHawkins@IntralinkSpine.com
"The smaller scale intrusive Réjuve treatment gives quick nearby basic support of the circle, versus simply utilizing an ESI to treat the agony."
Tweet this
"At the 3-month point, three of the four (3/4) patients have no (zero) low back torment. What's more, the fourth patient has practically no back agony; truth be told, she climbed the Sydney Harbor Bridge two-weeks after the treatment and just came back from exploring and moving in Europe!" says Lyle Hawkins, CEO of Intralink-Spine, Inc. (Message from CEO)
"We keep on being exceptionally satisfied with the patient results. In spite of the fact that restricted to four patients at this stage, these 3-month information are demonstrative that the Réjuve gadget has an additionally enduring impact on low back torment and incapacity than the exceptionally basic epidural steroid infusion (ESI)," says Hawkins. "On the off chance that our VAS and ODI slant lines proceed not surprisingly, Réjuve will have an exceptionally sensational effect on how patients are presently treated for low back torment. In this way, you can comprehend why we keep on being amped up for Réjuve."
"Inside days after the Réjuve treatment, we're seeing patient torment scores drop from 5-7 to 0 on the VAS torment scale, and inability scores drop from more than half to 0 on the ODI. These underlying clinical results exhibit a critical diminishment or disposal of agony, not only a slight lessening in torment, and these advantages are proceeding past the 3-month point. This is incredible news, particularly as we start our bigger crucial clinical studies in the quick months ahead," says Tom Hedman, Ph.D., who is the Chief Scientific Officer for ILS and Adjunct Associate Professor in the F. Joseph Halcomb III, M.D. Branch of Biomedical Engineering at the University of Kentucky. "The smaller scale intrusive Réjuve treatment gives prompt neighborhood basic support of the plate, versus simply utilizing an ESI to treat the torment."
"The patients got fluoroscopic picture guided infusions of the Réjuve medicinal gadget in the lumbar intervertebral circles, with two posterolateral infusions for each treated level", states orthopedic specialist, Dr. Harwant Singh at the Pantai Medical Center, Kuala Lumpur, Malaysia. "The patient ODI and VAS scores at the 3-month interim are great and empowering for the Réjuve treatment."
Contacts
Intralink-Spine Inc.
Lyle Hawkins, 502-419-8099
LHawkins@IntralinkSpine.com
No comments:
Post a Comment
Note: only a member of this blog may post a comment.